129 related articles for article (PubMed ID: 38009416)
21. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume.
Feng W; Zhang Q; Fu XL; Cai XW; Zhu ZF; Yang HJ; Xiang JQ; Zhang YW; Chen HQ
BMC Cancer; 2015 May; 15():348. PubMed ID: 25934006
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.
Torresan F; Cavedon E; Mian C; Iacobone M
World J Surg; 2018 Feb; 42(2):367-375. PubMed ID: 29134313
[TBL] [Abstract][Full Text] [Related]
23. Predicting Outcomes in Sporadic and Hereditary Medullary Thyroid Carcinoma over Two Decades.
Kotwal A; Erickson D; Geske JR; Hay ID; Castro MR
Thyroid; 2021 Apr; 31(4):616-626. PubMed ID: 33108969
[No Abstract] [Full Text] [Related]
24. Distant metastasis in medullary thyroid carcinoma: Clinical outcomes and implications of T stage.
Shao Y; Li G; Wei T; Gong R; Li Z; Zhu J; Lei J
Clin Endocrinol (Oxf); 2022 Nov; 97(5):676-684. PubMed ID: 35261045
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
[TBL] [Abstract][Full Text] [Related]
26. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
27. Role of postoperative radiotherapy after curative resection and adjuvant chemotherapy for patients with pathological stage N2 non-small-cell lung cancer: a propensity score matching analysis.
Kim BH; Kim HJ; Wu HG; Kang CH; Kim YT; Lee SH; Kim DW
Clin Lung Cancer; 2014 Sep; 15(5):356-64. PubMed ID: 24996882
[TBL] [Abstract][Full Text] [Related]
28. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
[No Abstract] [Full Text] [Related]
29. Cure and survival of sporadic medullary thyroid carcinoma following systematic preoperative calcitonin screening.
Torresan F; Mian C; Cavedon E; Iacobone M
Langenbecks Arch Surg; 2019 Jun; 404(4):411-419. PubMed ID: 30903267
[TBL] [Abstract][Full Text] [Related]
30. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
31. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
32. The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non-small Cell Lung Cancer.
Zhu F; Wang H; Ashamalla H
Clin Lung Cancer; 2022 Sep; 23(6):e384-e393. PubMed ID: 35676168
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit of surgery with postoperative radiotherapy in locally advanced cervical adenocarcinoma: a population-based analysis.
Wang X; Lu X; Chen J; Yi H; Lan Q
BMC Surg; 2023 Oct; 23(1):299. PubMed ID: 37789291
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
35. Effect of postoperative radiotherapy for patients with differentiated thyroid cancer.
Ryu H; Wu HG; Lee KE; Chung EJ; Ahn SH; Park YJ; Choi HS
Clin Endocrinol (Oxf); 2023 Jun; 98(6):803-812. PubMed ID: 36535908
[TBL] [Abstract][Full Text] [Related]
36. Postoperative Radiation Therapy in Oral Cavity Verrucous Carcinoma.
Naik AN; Silverman DA; Rygalski CJ; Zhao S; Brock G; Lin C; Puram SV; Rocco JW; Baliga S; VanKoevering KK; Old MO; Seim NB; Kang SY
Laryngoscope; 2022 Oct; 132(10):1953-1961. PubMed ID: 34989407
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer.
Kukulska A; Krajewska J; Kołosza Z; Grządziel A; Gajek M; Paliczka-Cieślik E; Syguła D; Ficek K; Kluczewska-Gałka A; Jarząb B
BMC Endocr Disord; 2021 Aug; 21(1):160. PubMed ID: 34372848
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma.
Groen AH; Beckham TH; Links TP; Goldman DA; Sherman EJ; Tuttle MM; Bijl HP; Wong RJ; Plukker JTM; Lee NY;
J Surg Oncol; 2020 Feb; 121(2):234-243. PubMed ID: 31733124
[TBL] [Abstract][Full Text] [Related]
39. The role of postoperative radiotherapy (PORT) in pulmonary large cell neuroendocrine carcinoma (PLCNEC).
Gang Jin ; Lili Xue ; Xiang Song
Cancer Radiother; 2020 Jun; 24(3):215-221. PubMed ID: 32156456
[TBL] [Abstract][Full Text] [Related]
40. National Trends in the Surgical Treatment of Non-advanced Medullary Thyroid Cancer (MTC): An Evaluation of Adherence with the 2009 American Thyroid Association Guidelines.
Chang EHE; Lutfi W; Feinglass J; Reiher AE; Moo-Young T; Bhayani MK
World J Surg; 2016 Dec; 40(12):2930-2940. PubMed ID: 27447700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
